SG11201501011WA - Methods for treating atopic dermatitis by administering an il-4r antagonist - Google Patents
Methods for treating atopic dermatitis by administering an il-4r antagonistInfo
- Publication number
- SG11201501011WA SG11201501011WA SG11201501011WA SG11201501011WA SG11201501011WA SG 11201501011W A SG11201501011W A SG 11201501011WA SG 11201501011W A SG11201501011W A SG 11201501011WA SG 11201501011W A SG11201501011W A SG 11201501011WA SG 11201501011W A SG11201501011W A SG 11201501011WA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonist
- administering
- methods
- atopic dermatitis
- treating atopic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697972P | 2012-09-07 | 2012-09-07 | |
| US201261738715P | 2012-12-18 | 2012-12-18 | |
| US201361748588P | 2013-01-03 | 2013-01-03 | |
| US201361764624P | 2013-02-14 | 2013-02-14 | |
| US201361768229P | 2013-02-22 | 2013-02-22 | |
| US201361770091P | 2013-02-27 | 2013-02-27 | |
| US201361782420P | 2013-03-14 | 2013-03-14 | |
| US201361816191P | 2013-04-26 | 2013-04-26 | |
| FR1356759 | 2013-07-10 | ||
| PCT/US2013/057898 WO2014039461A1 (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501011WA true SG11201501011WA (en) | 2015-03-30 |
Family
ID=50233497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701798TA SG10201701798TA (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| SG11201501011WA SG11201501011WA (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701798TA SG10201701798TA (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140072583A1 (en) |
| EP (3) | EP3354663A1 (en) |
| JP (3) | JP6353838B2 (en) |
| KR (3) | KR102576903B1 (en) |
| CN (1) | CN104995212A (en) |
| AR (1) | AR092475A1 (en) |
| AU (4) | AU2013312868B2 (en) |
| BR (1) | BR112015005048A8 (en) |
| CA (1) | CA2883936C (en) |
| CY (1) | CY1121906T1 (en) |
| DK (1) | DK2892927T3 (en) |
| ES (1) | ES2675779T3 (en) |
| HK (1) | HK1209132A1 (en) |
| HR (1) | HRP20181227T1 (en) |
| HU (1) | HUE039387T2 (en) |
| IL (1) | IL237328B (en) |
| LT (1) | LT2892927T (en) |
| MX (1) | MX363193B (en) |
| NZ (3) | NZ731864A (en) |
| PL (1) | PL2892927T3 (en) |
| RS (1) | RS57520B1 (en) |
| RU (2) | RU2698907C2 (en) |
| SG (2) | SG10201701798TA (en) |
| SI (1) | SI2892927T1 (en) |
| TR (1) | TR201808181T4 (en) |
| TW (3) | TWI690328B (en) |
| UY (1) | UY35013A (en) |
| WO (1) | WO2014039461A1 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2624865T3 (en) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| ES2701093T3 (en) | 2012-08-21 | 2019-02-20 | Sanofi Biotechnology | Methods to treat or prevent asthma by administering an IL-4R antagonist |
| DK2892927T3 (en) | 2012-09-07 | 2018-07-16 | Regeneron Pharma | METHODS OF TREATING ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST |
| TWI755763B (en) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
| CA2915839A1 (en) | 2013-06-21 | 2014-12-24 | Leda MANNENT | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TWI634900B (en) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| KR20230167770A (en) | 2014-02-21 | 2023-12-11 | 사노피 바이오테크놀로지 | Methods for treating or preventing asthma by administering an il-4r antagonist |
| RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
| WO2015195845A1 (en) * | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
| TW201628647A (en) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | Anti-IL4-IL13 bispecific antibodies |
| JP6861630B2 (en) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist |
| CA3232651A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| CA2980992C (en) | 2015-04-14 | 2024-01-23 | Akihisa Kaneko | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| AU2017220184B2 (en) * | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
| CN107474134B (en) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | Antibodies for binding interleukin-4 receptor |
| EP3506931A1 (en) * | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| KR20230006049A (en) | 2016-09-22 | 2023-01-10 | 리제너론 파아마슈티컬스, 인크. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| UA124269C2 (en) | 2016-09-23 | 2021-08-18 | Дженентек, Інк. | Uses of il-13 antagonists for treating atopic dermatitis |
| TWI784988B (en) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| PT3515465T (en) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| EP3703818B1 (en) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
| KR20200110302A (en) * | 2017-10-31 | 2020-09-23 | 원니스 바이오테크 컴퍼니 리미티드 | Treatment of IgE-mediated allergic diseases |
| CA3081751A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
| WO2019150607A1 (en) * | 2018-01-31 | 2019-08-08 | ＭｅｄｉＤｏｃ Ｓｅａｒｃｈ株式会社 | Advertisement presentation method and advertisement presentation system |
| KR20210010518A (en) * | 2018-05-13 | 2021-01-27 | 리제너론 파아마슈티컬스, 인크. | How to treat atopic dermatitis by administering an IL-4R inhibitor |
| SG11202100525SA (en) | 2018-08-10 | 2021-02-25 | Aclaris Therapeutics Inc | Pyrrolopyrimidine itk inhibitors |
| WO2020092015A1 (en) * | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11497718B2 (en) | 2018-11-13 | 2022-11-15 | Dermavant Sciences GmbH | Use of tapinarof for the treatment of atopic dermatitis |
| CN111494625B (en) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | Pharmaceutical compositions for the treatment of IL-4 and/or IL-13 mediated signal transduction related disorders |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CN111592597B (en) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | Interleukin 4 receptor (IL-4R) binding proteins and uses thereof |
| WO2021026203A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| BR112022000377A2 (en) | 2019-08-05 | 2022-05-10 | Regeneron Pharma | Methods for the treatment of atopic dermatitis by administration of an il-4r antagonist |
| US11748800B1 (en) * | 2019-09-11 | 2023-09-05 | Life Spectacular, Inc. | Generating skin care recommendations for a user based on skin product attributes and user location and demographic data |
| CN111825766B (en) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | anti-IL-4R single domain antibody and application thereof |
| JP2023504204A (en) | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | Methods of treating digitally identified IL-4/IL-13 related disorders |
| IL296214A (en) | 2020-03-27 | 2022-11-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4019547A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for il-4r and il-31 |
| EP4019090A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
| KR20230123993A (en) | 2020-12-23 | 2023-08-24 | 누맙 세러퓨틱스 아게 | Antibody variable domain that binds IL-31 |
| US11581084B2 (en) * | 2020-12-29 | 2023-02-14 | Kpn Innovations, Llc. | Systems and methods for generating an alimentary plan for managing skin disorders |
| CA3208215A1 (en) * | 2021-02-18 | 2022-08-25 | Paul Changelian | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions |
| CA3227014A1 (en) | 2021-08-23 | 2023-03-02 | Ashish Bansal | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| WO2023191665A1 (en) * | 2022-03-31 | 2023-10-05 | Milaboratory, Limited Liability Company | ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3315427B2 (en) * | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | Dermatitis treatment |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| CA2409267C (en) | 2000-05-26 | 2017-02-28 | Immunex Corporation | Interleukin-4 antagonists and compositions thereof |
| KR100572408B1 (en) * | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | True Positive Composition and Wound Healing Composition |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5234445B2 (en) * | 2004-10-05 | 2013-07-10 | 源一郎 杣 | Drug |
| US7531637B2 (en) | 2005-05-06 | 2009-05-12 | Zymogenetics, Inc. | IL-31 monoclonal antibodies |
| ATE537190T1 (en) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2624865T3 (en) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| RU2453303C1 (en) * | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Pharmaceutical composition for atopic dermatitis |
| DK2892927T3 (en) | 2012-09-07 | 2018-07-16 | Regeneron Pharma | METHODS OF TREATING ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST |
-
2013
- 2013-09-04 DK DK13765844.9T patent/DK2892927T3/en active
- 2013-09-04 MX MX2015002873A patent/MX363193B/en unknown
- 2013-09-04 WO PCT/US2013/057898 patent/WO2014039461A1/en active Application Filing
- 2013-09-04 JP JP2015531149A patent/JP6353838B2/en active Active
- 2013-09-04 KR KR1020227011429A patent/KR102576903B1/en active IP Right Grant
- 2013-09-04 BR BR112015005048A patent/BR112015005048A8/en not_active Application Discontinuation
- 2013-09-04 KR KR1020157008872A patent/KR102122708B1/en active IP Right Grant
- 2013-09-04 EP EP18161065.0A patent/EP3354663A1/en not_active Withdrawn
- 2013-09-04 LT LTEP13765844.9T patent/LT2892927T/en unknown
- 2013-09-04 SG SG10201701798TA patent/SG10201701798TA/en unknown
- 2013-09-04 TR TR2018/08181T patent/TR201808181T4/en unknown
- 2013-09-04 NZ NZ731864A patent/NZ731864A/en unknown
- 2013-09-04 HU HUE13765844A patent/HUE039387T2/en unknown
- 2013-09-04 PL PL13765844T patent/PL2892927T3/en unknown
- 2013-09-04 KR KR1020217023487A patent/KR102385501B1/en active IP Right Grant
- 2013-09-04 EP EP21167811.5A patent/EP3889181B1/en active Active
- 2013-09-04 US US14/017,333 patent/US20140072583A1/en not_active Abandoned
- 2013-09-04 NZ NZ630178A patent/NZ630178A/en unknown
- 2013-09-04 SI SI201331084T patent/SI2892927T1/en unknown
- 2013-09-04 EP EP13765844.9A patent/EP2892927B1/en not_active Revoked
- 2013-09-04 AU AU2013312868A patent/AU2013312868B2/en active Active
- 2013-09-04 CN CN201380046623.6A patent/CN104995212A/en active Pending
- 2013-09-04 ES ES13765844.9T patent/ES2675779T3/en active Active
- 2013-09-04 CA CA2883936A patent/CA2883936C/en active Active
- 2013-09-04 RU RU2018131237A patent/RU2698907C2/en active
- 2013-09-04 RU RU2015108073A patent/RU2666630C2/en active
- 2013-09-04 NZ NZ748451A patent/NZ748451A/en unknown
- 2013-09-04 SG SG11201501011WA patent/SG11201501011WA/en unknown
- 2013-09-04 RS RS20180802A patent/RS57520B1/en unknown
- 2013-09-05 TW TW102131927A patent/TWI690328B/en active
- 2013-09-05 TW TW107106951A patent/TWI699212B/en active
- 2013-09-05 TW TW111134046A patent/TWI814575B/en active
- 2013-09-06 AR ARP130103184A patent/AR092475A1/en unknown
- 2013-09-06 UY UY0001035013A patent/UY35013A/en unknown
-
2015
- 2015-02-19 IL IL237328A patent/IL237328B/en unknown
- 2015-09-29 HK HK15109558.8A patent/HK1209132A1/en not_active IP Right Cessation
-
2017
- 2017-05-31 US US15/610,267 patent/US20170333557A1/en not_active Abandoned
-
2018
- 2018-06-08 JP JP2018109925A patent/JP6637113B2/en active Active
- 2018-06-18 AU AU2018204346A patent/AU2018204346B2/en active Active
- 2018-07-27 CY CY20181100782T patent/CY1121906T1/en unknown
- 2018-07-31 HR HRP20181227TT patent/HRP20181227T1/en unknown
-
2019
- 2019-12-10 AU AU2019279946A patent/AU2019279946B2/en active Active
-
2021
- 2021-09-23 AU AU2021236538A patent/AU2021236538B2/en active Active
-
2022
- 2022-09-23 US US17/951,987 patent/US20230058395A1/en active Pending
-
2023
- 2023-03-29 JP JP2023052545A patent/JP2023082091A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181227T1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| HRP20181963T1 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| HK1222567A1 (en) | Methods for treating nasal polyposis by administering an il-4r antagonist il-4r | |
| ZA201906339B (en) | Methods for treating pruritus | |
| ZA201407459B (en) | Method and apparatus for subscription sharing | |
| EP2851378A4 (en) | Method for producing oxymethylene copolymer | |
| IL278968B (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
| IL271284A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| EP2736517A4 (en) | Pharmaceutical composition for treating atopic dermatitis | |
| HUE046410T2 (en) | Methods for treating nasal polyposis by administering an il-4r antagonist |